Clinical Trials
50 trialsPhase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
M.D. Anderson Cancer Center
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Jonsson Comprehensive Cancer Center
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
RABBIT
University of Arizona
Lumed
University Hospital, Basel, Switzerland
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Shanghai Jiao Tong University School of Medicine
CAST-MTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
M.D. Anderson Cancer Center
CMTpostopFDOPA
Institut Claudius Regaud
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
Peking Union Medical College Hospital
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
GFRα4 CAR T Cells in MTC Patients
University of Pennsylvania
MIMETIC
University Medical Center Groningen
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
Instituto do Cancer do Estado de São Paulo
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
First Affiliated Hospital of Fujian Medical University
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
University College, London
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
Icahn School of Medicine at Mount Sinai
iTEP-CMT
Nantes University Hospital
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
University Hospital, Basel, Switzerland
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Columbia University
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
GRAN-T-MTC
Azienda Ospedaliero, Universitaria Pisana
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
University of Wisconsin, Madison
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
University of Pennsylvania
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TEPCMT
Assistance Publique Hopitaux De Marseille
Iodine I 131 in Treating Patients With Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Thalidomide in Treating Patients With Thyroid Cancer
University of Kentucky
Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Massachusetts General Hospital
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Federico II University
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
M.D. Anderson Cancer Center
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Duke University
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Yale University
Biological Therapy in Treating Patients With Metastatic Cancer
Duke University
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
DOPMET
Assistance Publique - Hôpitaux de Paris
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Case Comprehensive Cancer Center